AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Novavax Q2 Earnings Beat Expectations, Raises 2025 Revenue Outlook on COVID Shot Collaborations
ByAinvest
Wednesday, Aug 6, 2025 8:56 am ET1min read
Novavax reported Q2 revenue of $239.2M, beating expectations, and raised its 2025 revenue outlook. The company cited collaborations related to its COVID-19 shot, Nuvaxovid, as a key factor in its improved outlook. Shares traded higher in the premarket.
Novavax (NASDAQ: NVAX) reported a robust second-quarter (Q2) financial performance, with revenue of $239.2 million, exceeding market expectations. The Maryland-based biotech company also raised its 2025 revenue outlook, citing collaborations related to its COVID-19 vaccine, Nuvaxovid, as a key factor in its improved outlook [1].The company's shares traded higher in the premarket following the announcement. Novavax's Q2 revenue was driven largely by the FDA's approval of the Biologics License Application (BLA) for Nuvaxovid, which was approved for adults aged 65 and older and for individuals aged 12–64 at high risk of severe outcomes [2].
Novavax now expects full-year revenue between $1 billion and $1.05 billion, up from its previous range of $975 million to $1.025 billion. This upward revision is attributed to a $175 million milestone payment from Sanofi (NASDAQ: SNY) following the U.S. approval of Nuvaxovid. Additionally, early data from a Phase 3 trial showed strong immune responses for Novavax’s COVID-19-influenza combination and stand-alone flu vaccine candidates, suggesting potential for longer protection [2].
The company completed the handover of U.S. commercial leadership for Nuvaxovid to Sanofi ahead of the 2025–2026 vaccination season. Marketing authorizations in the U.S. and EU are expected to transfer to Sanofi in the fourth quarter, triggering an additional $50 million in milestone payments [2].
While Novavax has shown strong quarterly performance, its stock has faced challenges over the past year, including a series of earnings misses. However, the company's latest results and outlook indicate a potential turnaround, driven by its COVID-19 vaccine and collaboration with Sanofi [3].
References:
[1] https://seekingalpha.com/news/4479761-novavax-stock-higher-q2-beat-guidance
[2] https://www.investing.com/news/earnings/novavax-lifts-2025-revenue-outlook-after-fda-milestone-payment-4173292
[3] https://seekingalpha.com/news/4478803-novavax-q2-2025-earnings-preview
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet